Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Trial of Anti-PD-1 Checkpoint Inhibitor Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

Trial Profile

Phase I/II Trial of Anti-PD-1 Checkpoint Inhibitor Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Nivolumab (Primary)
  • Indications Neuroendocrine tumours; Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Nov 2018 Status changed from recruiting to active, no longer recruiting.
    • 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top